Who
Joseph S. Zakrzewski
Director
Company insider
Files Form 4 as: Director, AN2 Therapeutics; Director, Cyteir Therapeutics; Director, Sangamo Therapeutics; Chief Executive Officer, Amarin Corporation; Director, Acceleron Pharma; Director, Insulet; Director, Liposcience; Director, Dov Pharmaceutical.
In numbers
- Trades disclosed
- 253
- Buys
- 32
- Sells
- 22
- Bought
- $805K
- Sold
- $52.7M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 8 May 2008
- Last trade
- 14 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 14 Aug 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code G | —405,880 at $0.00 | filing |
| 14 Aug 2026filed 14 Aug 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code G | —405,880 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —99,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —99,999 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,111 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,523 at $0.00 | filing |
| 19 Dec 2024filed 23 Dec 2024 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,816 at $0.00 | filing |
| 27 Nov 2024filed 27 Nov 2024 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,8002,000 at $1.40 | filing |
News
Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKKGY) Financial ReviewAMRN · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Joseph S. Zakrzewski; 1 article from the last 14 days about the 3 companies they traded most, at most three about any one of them.